Evgen Pharma PLC Appoints Chief Medical Officer (6374K)
04 Gennaio 2016 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 6374K
Evgen Pharma PLC
04 January 2016
For immediate release 4 January 2016
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Appoints Chief Medical Officer
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce the appointment of Dr Hamina J
Patel MB BCh MSc MRCPI as Chief Medical Officer.
Dr Patel is a pharmaceutical executive with more than 15 years'
industry experience, leading global cross functional teams in the
development and commercialisation of drugs primarily within the
field of oncology.
Dr Patel was previously Director of Drug Development, Oncology,
at Johnson and Johnson, where she helped to build a broad and
differentiated portfolio of indications for the cancer drug
VELCADE(R) and was instrumental in the success of a new indication
(the second-line treatment of mantle cell lymphoma) based on a
Phase II clinical study in more than 35 countries. She received
numerous awards for her contribution to the Oncology group at
Johnson and Johnson, including a Standard of Leadership award.
In addition to her small molecule expertise, Dr Patel has worked
extensively in the development of biopharmaceuticals at Celltech
and at Chugai.
Dr Patel qualified as a physician in 1990 and worked for almost
ten years in hospitals around the UK before moving into the
pharmaceutical industry.
Dr Stephen Franklin, Evgen Pharma's CEO, commented: "We are
delighted to announce the appointment of Dr Hamina Patel as Evgen's
Chief Medical Officer. Hamina has an impressive track record at
global pharmaceutical companies and a breadth of relevant clinical
experience. Her appointment strengthens the core team at Evgen and
will be of great value in the delivery of our upcoming Phase II
clinical trials in metastatic breast cancer and in subarachnoid
haemorrhage, both of which are on track to begin this year."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
www.evgen.com
Buchanan +44 (0) 20 7466
Mark Court, Sophie Cowles, Stephanie Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita Mitropoulou
(Corporate Finance) +44 (0) 20 7382
John Howes, Mark Treharne (Corporate Broking) 1100
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based
in Liverpool, UK, at the Liverpool Science Park. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG. For further information please visit
www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIGDBSGGBGLX
(END) Dow Jones Newswires
January 04, 2016 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024